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ABSTRACT  
Routine data from electronic health records (EHRs) provide insights into links between herpes zoster 
(HZ) and cardiovascular complications such as stroke or myocardial infarction (MI) in different 
populations worldwide. Evidence from large EHR studies using both self-controlled case series and 
traditional cohort designs suggests that there is a transient increase in the risk of stroke after HZ, 
which gradually resolves over 6 to 12 months. In these studies, herpes zoster ophthalmicus was 
associated with a higher risk of stroke than HZ at other sites. A larger effect size was seen in people 
aged under 40 years. Existing studies also suggest that HZ may have a triggering effect on MI, 
although fewer studies examine this outcome. Further evidence is needed on the effectiveness and 
cost-effectiveness of vaccine and antiviral drugs to reduce cardiovascular complications after HZ, in 
studies which are designed to minimise selection biases and confounding by indication. 
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Introduction 
Acute infections, such as influenza, can trigger cardiovascular events including stroke and myocardial 
infarction (MI)1,2. Interest is growing in the effect of persistent reactivating viruses such as varicella 
zoster virus (VZV) on the pathogenesis of cardiovascular diseases, which are the leading global cause 
of death. There are biologically plausible mechanisms through which VZV could trigger acute 
vascular events: inflammatory responses following reactivation of VZV from latency to cause herpes 
zoster (HZ) may lead to endothelial dysfunction and development of a hyper-coagulable state3. 
Pathological vascular remodelling associated with arterial VZV infection (VZV vasculopathy) may also 
contribute to vascular risk4. As the population ages, the burden of disease due to stroke, including 
disability, illness and premature death, is projected to double worldwide by 20305. Understanding 
the current evidence and its limitations is crucial to inform vaccination and treatment strategies to 
minimise vascular complications of VZV. 
 
Evidence for association between HZ and vascular complications 
Historically, the ability to investigate relatively rare complications of infections was hampered by 
lack of power due to small sample sizes. Now, in the era of “big data”, with routinely collected 
electronic health records (EHRs) available for large numbers of patients with clinically-diagnosed HZ 
infections, vascular complications can be investigated in different population subgroups with 
increasing precision. There remain, however, methodological difficulties with interpreting data 
robustly from studies with different designs, exposure and outcome definitions, populations and 
settings. In the last year, several systematic reviews synthesized evidence of the relationship 
between HZ and stroke from cohort and self-controlled case series studies6–11. Although the pooled 
effect estimates presented in these reviews vary due to differing methods and inclusion criteria, the 
combined evidence suggests the following: 
1) HZ can trigger stroke.  
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There is a transient increase in the risk of stroke after HZ, which is highest in the earliest time period 
after HZ diagnosis – adjusted incidence ratio (IR) for stroke 2.37 (95% CI 2.17-2.59) up to one week 
after HZ12 – and gradually diminishes to baseline by around six to twelve months. At four weeks. 
data from three powerful self-controlled case series studies using primary care EHRs from the US, UK 
and Germany, show a pooled IR for stroke of 1.55 (95% C.I. 1.46-1.65)12–14. These studies have the 
major benefit of implicitly controlling for fixed between-person confounding effects15. The findings 
are corroborated by several prospective cohort studies using data from Asian, European and US 
populations, which show a similar gradient of stroke risk up to one year16–21. Evidence for any longer-
term effect of HZ on vascular risk is mixed, with marked heterogeneity between studies. A meta-
analysis of four cohort studies using random effects found no association between HZ and stroke 
after one year: pooled OR 1.20 (95% CI 0.82-1.75)11. 
2) Herpes zoster ophthalmicus (HZO) leads to a higher risk of stroke than HZ at other sites. 
Point estimates for the effect of HZO on stroke are generally higher than those for HZ at other or 
unspecified sites. HZO refers to reactivation of VZV in the first division of the trigeminal nerve, and it 
has been proposed that the proximity of the trigeminal ganglion to cerebral arteries may increase 
these patients’ susceptibility to large vessel stroke.11 However, many EHR studies do not specify 
zoster site, which is likely to lead to underestimation of effect because some HZ at unclassified sites 
could actually be HZO. The stronger effect for HZO was noted in two self-controlled case series 
studies which stratified by HZ site12,13 as well as two Asian cohort studies20,21. A further study found 
no effect of HZ site on long-term stroke risk, although few participants had HZO records22. 
3) Stroke risk may be highest for younger people with HZ 
Intriguing evidence suggests a more marked effect in younger people. Point estimates for the effect 
of HZ on stroke are highest for younger people, aged less than 40 years, although the relatively small 
numbers of strokes in this age group mean that confidence intervals tend to overlap with those for 
5 
 
older ages. Of five cohort studies which stratified by age, four found a greater effect in younger age 
groups16,17,22,23 and one study showed no difference in effect size by age20. 
4) HZ can trigger myocardial infarction (MI) 
One self-controlled case series study using US Medicare data12 showed a similar though smaller 
transient triggering effect of HZ on MI – IR 1.68 (95% CI 1.47 – 1.92) – for week one after HZ. An 
elevated risk of acute coronary syndrome (ACS) or MI up to 3 months after HZ was also suggested by 
combined results from two prospective population cohort studies from the US18 and Taiwan24: 
pooled OR 1.34 (95% 0.98 to 1.82)11, although this just failed to reach statistical significance in a 
random effects model. The Taiwanese study also showed a small increase in ACS risk associated with 
HZ in follow up to 12 years (HR 1.10 (95% CI 1.02 to 1.19)24, which was mirrored in a cohort using UK 
primary care data with follow up to 24 years22.  
Table 1 
Effect of HZ prevention on vascular complications 
It seems plausible that reducing HZ incidence and severity through vaccination is likely to result in 
fewer vascular complications. A single dose of the live attenuated zoster vaccine (Zostavax) reduces 
herpes zoster incidence by around 50%.25 However, at present evidence of direct cardiovascular 
benefit from the live attenuated zoster vaccine is lacking: in the Shingles Prevention Study, rates of 
serious adverse events including MI and stroke, were the same in recipients of vaccine and placebo 
but follow up was short (to 42 days) and the trial was not powered for these endpoints25. 
Observational safety studies have also shown no effect of Zostavax on stroke risk in follow up to 5-6 
weeks26,27, although longer-term follow up is needed to assess fully the vaccine’s effectiveness 
against vascular outcomes. The recent development of the highly efficacious subunit vaccine HZ/su 
(Shingrix), which reduces HZ incidence by 90% after two doses in older adults28 has potential for 
major impact on VZV disease burden, including vascular complications, in settings achieving good 
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vaccine uptake. A recent modelling study based on RCT data showed that Shingrix, at a price of $280 
for two doses, was more cost effective than Zostavax (current price $213 per dose).29 
 
Effect of HZ treatment on vascular complications 
It remains uncertain whether antiviral agents used to treat HZ alter the risk of vascular events: 
results from one cohort study19 and one self-controlled case series study13 suggest that patients 
receiving antivirals may have a lower stroke risk than patients not taking antivirals, especially earlier 
after HZ diagnosis. Another cohort study, however, found no difference in stroke risk at one year 
between those who did and did not receive antivirals for HZO21, although data on timing and 
duration of treatment were unavailable in this study and it was difficult to exclude confounding by 
indication – the situation in which patients who were more unwell and had a higher risk of vascular 
complications preferentially received antiviral treatment.  
 
Conclusions 
In future, our ability to prevent HZ-induced vascular events will depend upon improving 
understanding of the nature of risk including any effects of sub-clinical VZV reactivation or long-term 
effects. Large-scale population-based studies to identify the characteristics of affected patients will 
help to guide intervention targeting. Adequately powered studies of HZ prevention and treatment 
strategies against specific vascular endpoints are needed, which are carefully designed to avoid 
selection biases and confounding by indication. As the evidence base develops, it will be important 
to (re-)assess the cost effectiveness of policy options such as introducing universal varicella 
vaccination in countries where it is not routine, for example in Northern Europe, or expanding 
recommendations for zoster vaccination to include younger age groups at high cardiovascular risk.  
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